Cullinan oncology announces u.s. fda clearance of investigational new drug application for cln-617, a novel fusion protein harnessing il-2 and il-12 cytokines

Cambridge, mass., march 27, 2023 (globe newswire) -- cullinan oncology, inc. (nasdaq: cgem), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the u.s. food and drug administration (fda) has cleared its investigational new drug (ind) application for cln-617, a fusion protein comprised of two potent and synergistic antitumor cytokines, il-2 and il-12, with a collagen binding domain designed for retention in the tumor microenvironment (tme) following intratumoral injection. cullinan oncology will initially evaluate cln-617 in a phase 1 trial in patients with advanced solid tumors.
CGEM Ratings Summary
CGEM Quant Ranking